A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giuseppe Giaccone,Rachel E Sanborn,Saiama N Waqar,Alex Martinez-Marti,Santiago Ponce,Huiling Zhen,Gerard Kennealey,Susan Erickson-Viitanen,Eric Schaefer

Clinical Lung Cancer（2018）

Cited 15|Views29

No score

Abstract

Ruxolitinib 15 mg b.i.d. had an acceptable safety profile in combination with pemetrexed/cisplatin asfirst-line treatment of patients with stage IIIB/IV or recurrent nonsquamous NSCLC and systemic inflammation. Early study termination limited the interpretation of efficacy data in the randomized phase II part of the study.

Translated text

Key words

Janus kinase (JAK),JAK1,JAK2,Modified Glasgow prognostic score,Signal transducers and activators of transcription (STAT)

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined